WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience behavioral testing systems
 QUICK SEARCH:   [advanced]


     
-


HOME
  |  
SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Polli, J. W.
Right arrow Articles by Kincaid, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Polli, J. W.
Right arrow Articles by Kincaid, R. L.

 Previous Article  |  Next Article 

Journal of Neuroscience, Vol 14, 1251-1261, Copyright © 1994 by Society for Neuroscience


ARTICLE

Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation

JW Polli and RL Kincaid
Section on Immunology, National Institute on Alcohol Abuse and Alcoholism, Rockville, Maryland 20852.

Cyclic nucleotide-dependent protein phosphorylation plays a central role in neuronal signal transduction. Neurotransmitter-elicited increases in cAMP/cGMP brought about by activation of adenylyl and guanylyl cyclases are downregulated by multiple phosphodiesterase (PDE) enzymes. In brain, the calmodulin (CaM)-dependent isozymes are the major degradative activities and represent a unique point of intersection between the cyclic nucleotide- and calcium (Ca2+)-mediated second messenger systems. Here we describe the distribution of the PDE1B1 (63 kDa) CaM-dependent PDE in mouse brain. An anti-peptide antiserum to this isoform immunoprecipitated approximately 30-40% of cytosolic PDE activity, whereas antiserum to PDE1A2 (61 kDa isoform) removed 60-70%, demonstrating that these isoforms are the major CaM- dependent PDEs in brain. Quantification of PDE1B1 immunoreactivity on immunoblots indicated that striatum contains 3-17-fold higher levels of PDE1B1 than other brain regions, with lowest immunoreactivity in cerebellum. In situ hybridization demonstrated high levels of PDE1B1 mRNA in the caudate-putamen, nucleus accumbens, and olfactory tubercle. Moderate mRNA levels were observed in dentate gyrus, cerebral cortex, medial thalamic nuclei, and brainstem, whereas negligible mRNA was detectable in the globus pallidus, islands of Calleja, substantia nigra, and ventral tegmental area. Immunocytochemistry confirmed that the majority of PDE1B1 protein was localized to the caudate-putamen, nucleus accumbens, and olfactory tubercle. Within the caudate-putamen, PDE1B1 immunoreactivity was ubiquitous, while PDE1A2 immunostaining was restricted to a minor subset of striatal neurons. The expression of PDE1B1 protein and mRNA correlate strongly with areas of the brain that are richest in dopaminergic innervation; indeed, there are strikingly similar distributions for PDE1B1 and D1 dopamine receptor mRNAs. Since D1 receptor binding activates adenylyl cyclase, and striatal neurons lack CaM-sensitive forms of cyclase, the high amount of this PDE implies an important physiological role for Ca(2+)-regulated attenuation of cAMP-dependent signaling pathways following dopaminergic stimulation.


This article has been cited by other articles:


Home page
J. Neurosci.Home page
A. Nishi, M. Kuroiwa, D. B. Miller, J. P. O'Callaghan, H. S. Bateup, T. Shuto, N. Sotogaku, T. Fukuda, N. Heintz, P. Greengard, et al.
Distinct Roles of PDE4 and PDE10A in the Regulation of cAMP/PKA Signaling in the Striatum
J. Neurosci., October 15, 2008; 28(42): 10460 - 10471.
[Abstract] [Full Text] [PDF]


Home page
Genome ResHome page
M. de Chaldee, M.-C. Gaillard, N. Bizat, J.-M. Buhler, O. Manzoni, J. Bockaert, P. Hantraye, E. Brouillet, and J.-M. Elalouf
Quantitative Assessment of Transcriptome Differences Between Brain Territories
Genome Res., July 1, 2003; 13(7): 1646 - 1653.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
T. M. Reed, D. R. Repaske, G. L. Snyder, P. Greengard, and C. V. Vorhees
Phosphodiesterase 1B Knock-Out Mice Exhibit Exaggerated Locomotor Hyperactivity and DARPP-32 Phosphorylation in Response to Dopamine Agonists and Display Impaired Spatial Learning
J. Neurosci., June 15, 2002; 22(12): 5188 - 5197.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
S. G. Andreeva, P. Dikkes, P. M. Epstein, and P. A. Rosenberg
Expression of cGMP-Specific Phosphodiesterase 9A mRNA in the Rat Brain
J. Neurosci., November 15, 2001; 21(22): 9068 - 9076.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Fujishige, J. Kotera, H. Michibata, K. Yuasa, S.-i. Takebayashi, K. Okumura, and K. Omori
Cloning and Characterization of a Novel Human Phosphodiesterase That Hydrolyzes Both cAMP and cGMP (PDE10A)
J. Biol. Chem., June 25, 1999; 274(26): 18438 - 18445.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
P. Calabresi, P. Gubellini, D. Centonze, G. Sancesario, M. Morello, M. Giorgi, A. Pisani, and G. Bernardi
A Critical Role of the Nitric Oxide/cGMP Pathway in Corticostriatal Long-Term Depression
J. Neurosci., April 1, 1999; 19(7): 2489 - 2499.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. Y. Lew, A. Garcia-Espana, K. Y. Lee, K. D. Carr, M. Goldstein, J. W. Haycock, and E. Meller
Increased Site-Specific Phosphorylation of Tyrosine Hydroxylase Accompanies Stimulation of Enzymatic Activity Induced by Cessation of Dopamine Neuronal Activity
Mol. Pharmacol., February 1, 1999; 55(2): 202 - 209.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
J. Kotera, K. Fujishige, H. Akatsuka, Y. Imai, N. Yanaka, and K. Omori
Novel Alternative Splice Variants of cGMP-binding cGMP-specific Phosphodiesterase
J. Biol. Chem., October 9, 1998; 273(41): 26982 - 26990.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
A. Nishi, G. L. Snyder, and P. Greengard
Bidirectional Regulation of DARPP-32 Phosphorylation by Dopamine
J. Neurosci., November 1, 1997; 17(21): 8147 - 8155.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
N. A. Otmakhova and J. E. Lisman
D1/D5 Dopamine Receptor Activation Increases the Magnitude of Early Long-Term Potentiation at CA1 Hippocampal Synapses
J. Neurosci., December 1, 1996; 16(23): 7478 - 7486.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Bofill-Cardona, O. Kudlacek, Q. Yang, H. Ahorn, M. Freissmuth, and C. Nanoff
Binding of Calmodulin to the D2-Dopamine Receptor Reduces Receptor Signaling by Arresting the G Protein Activation Switch
J. Biol. Chem., October 13, 2000; 275(42): 32672 - 32680.
[Abstract] [Full Text] [PDF]



-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help

-
Copyright 2008 by Society for Neuroscience ONLINE ISSN: 1529-2401
-